{"nctId":"NCT00631475","briefTitle":"Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443","startDateStruct":{"date":"2008-04"},"conditions":["Idiopathic Pulmonary Fibrosis"],"count":128,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Bosentan"]}],"interventions":[{"name":"Bosentan","otherNames":["Tracleer"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients should have completed all the assessments from the BUILD 3 (NCT00391443) end of study (EOS) visit.\n\n* Signed informed consent prior to initiation of any study-related procedures.\n* Women of childbearing potential must have a negative serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination.\n\nExclusion Criteria:\n\n* Any major violation of protocol AC-052-321 / BUILD 3 (NCT00391443).\n* Pregnancy or breast-feeding.\n* AST and/or ALT \\> 3 times the upper limit of the normal range.\n* Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.\n* Known hypersensitivity to bosentan or any of the excipients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)","description":"Mean extent of exposure to bosentan treatment in months","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"4.6"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Exposed to Bosentan Over Time","description":"Numbers of participants exposed to bosentan treatment over time","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events (AE) Leading to Discontinuation of Study Drug.","description":"Number of participants with at least one AE that led to permanent discontinuation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment-emergent Serious Adverse Events (SAE)","description":"Number of participants with at least one SAE during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.","description":"Number of participants with an increase in ALT and/or AST to \\> 3 times upper limit of normal during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":51,"n":128},"commonTop":["LIVER FUNCTION TEST ABNORMAL","DYSPNOEA","IDIOPATHIC PULMONARY FIBROSIS","OEDEMA PERIPHERAL"]}}}